Flavonoids and polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder affecting women, characterized by irregular menstrual cycles, elevated androgen levels, and ovulatory dysfunction. Current clinical treatments, such as combined oral contraceptive pills (COCP), metformin, and clomiphene, can alleviate symptoms but are often associated with adverse effects including gastrointestinal discomfort, the risk of ovarian hyperstimulation syndrome (OHSS), and potential deterioration of cardiometabolic indices. Thus, there is an urgent need for safer and well-tolerated alternative therapies. Flavonoids, a class of naturally occurring polyphenolic compounds, are widely distributed in various foods and medicinal plants. This review systematically analyzes evidence from preclinical and clinical studies. Preclinical studies demonstrate that flavonoids effectively mitigate oxidative stress and chronic low-grade inflammation in PCOS models by activating the Nrf2 antioxidant pathway, inhibiting NF-κB and NLRP3 inflammasomes, and activating the AMPK signaling pathway. These regulatory mechanisms translate into specific pathological improvements, including significantly reduced serum androgen and insulin levels, as well as the repair of abnormal ovarian morphology. Further clinical trials have confirmed the therapeutic potential of flavonoids. Compounds such as quercetin, soy isoflavones, and puerarin have been shown to significantly improve endocrine and metabolic indicators and optimize…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.